Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 2/2017

01-06-2017 | Images

Bullous Pyoderma Gangrenosum Associated with Hairy Cell Leukemia and Its Complete Response to Cladribine Therapy

Authors: Ankur Jain, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra, Amanjit Bal, Nabhajit Mallik, Narendar Kumar, Subhash Varma

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2017

Login to get access

Abstract

Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis seen in association with systemic disorders including hematologic malignancies. Hairy cell leukemia (HCL) however, is an unusual association of PG. We describe a 49-year old lady who presented to our hematology clinic with easy fatiguability and ulcerative skin lesions of 6 months duration. Examination revealed pallor and massive splenomegaly. Indurated, ulcerated lesion with undermined edges and necrotic base was observed on left thigh. Investigations revealed pancytopenia and bone marrow examination identified typical hairy cells. Flow cytometry of marrow aspirate was suggestive of classical HCL. BRAF V600E mutation was detected in peripheral blood by reverse transcriptase polymerase chain reaction. Skin biopsy revealed neutrophilic dermatosis and findings classical of bullous PG. Cladribine therapy (0.09 mg/kg/day by continuous intravenous infusion for 7 days) led to remission of both HCL and PG after a duration of 4 weeks. Cladribine monotherapy in a case of PG with HCL may avoid the additional immunosuppresion risk imposed by treating PG separately with corticosteroids. Immunosuppressive role of cladribine might be helpful in treating PG concurrent with HCL.
Literature
1.
go back to reference Svecová D, Pallová A, Chmurová N, Babal P (2008) Paraneoplastic vasculitis associated with hairy cell leukemia. Prague Med Rep 109:83–87PubMed Svecová D, Pallová A, Chmurová N, Babal P (2008) Paraneoplastic vasculitis associated with hairy cell leukemia. Prague Med Rep 109:83–87PubMed
2.
go back to reference Tombak A, Aygun S, Serinsoz E, Tiftik EN (2015) Complete recovery of pyoderma gangrenosum after successful treatment of underlying hairy cell leukemia with cladribine. Korean J Intern Med 30:739–741CrossRefPubMedPubMedCentral Tombak A, Aygun S, Serinsoz E, Tiftik EN (2015) Complete recovery of pyoderma gangrenosum after successful treatment of underlying hairy cell leukemia with cladribine. Korean J Intern Med 30:739–741CrossRefPubMedPubMedCentral
4.
go back to reference Saigal R, Singh Y, Mittal M, Kansal A, Maharia HR (2010) Pyoderma gangrenosum. J Assoc Phys India 58:378–383 Saigal R, Singh Y, Mittal M, Kansal A, Maharia HR (2010) Pyoderma gangrenosum. J Assoc Phys India 58:378–383
5.
go back to reference Finan MC, Su WP, Li CY (1984) Cutaneous findings in hairy cell leukemia. J Am Acad Dermatol 11:788–797CrossRefPubMed Finan MC, Su WP, Li CY (1984) Cutaneous findings in hairy cell leukemia. J Am Acad Dermatol 11:788–797CrossRefPubMed
6.
go back to reference Crow KK, Bowers RE (1974) Bullous haemorrhagic ulceration, a variant of pyoderma gangrenosum. Trans St Johns Hasp Dermatol Soc 60:142–151 Crow KK, Bowers RE (1974) Bullous haemorrhagic ulceration, a variant of pyoderma gangrenosum. Trans St Johns Hasp Dermatol Soc 60:142–151
7.
go back to reference Sigal DS, Miller HJ, Schram ED, Saven A (2010) Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood 116:2884–2896CrossRefPubMed Sigal DS, Miller HJ, Schram ED, Saven A (2010) Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood 116:2884–2896CrossRefPubMed
Metadata
Title
Bullous Pyoderma Gangrenosum Associated with Hairy Cell Leukemia and Its Complete Response to Cladribine Therapy
Authors
Ankur Jain
Deepesh Lad
Gaurav Prakash
Alka Khadwal
Pankaj Malhotra
Amanjit Bal
Nabhajit Mallik
Narendar Kumar
Subhash Varma
Publication date
01-06-2017
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2017
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-016-0713-8

Other articles of this Issue 2/2017

Indian Journal of Hematology and Blood Transfusion 2/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine